Literature DB >> 507087

Renal function in gout. V. Factors influencing the renal hemodynamics.

T F Yü, L Berger, D J Dorph, H Smith.   

Abstract

Renal hemodynamics as measured by inulin clearance (Cinulin) and para-aminohippurate clearance (CPAH) was evaluated in 149 patients with primary gout over intervals of two to 22 years. In over 30 per cent of the patients plasma urate was greater than 10 mg/dl and urinary uric acid greater than 800 mg/min. A linear trend in decreasing frequency of hyperuricemia and excessive uricosuria is significantly related to the patient's age at the onset of gout. Group I consisted of 84 patients with uncomplicated gout in both clearance studies. Cinulin and CPAH were somewhat lower in patients larger than or equal to 50 years of age with longer duration of gout. Further reduction in clearances was minimal at the second clearance study in intervals of approximately 10 years. Group II included 27 patients who had no associated disease at the time of the first clearance study but in whom associated disease had developed by the time of the second clearance study. A striking reduction in Cinulin and CPAH was noted, especially in those 50 years old or above. There were 38 patients in group III with associated diseases at the time of both clearance studies. They had lower Cinulin and CPAH at the time of the first study, particularly the older patients. Further reduction during the second study was less striking than that in group II. Analyses of variance suggest that various coexisting vascular diseases with associated nephropathy have the most significant impact on the status of renal function in gout, with aging the second most important and duration of gout, the third.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 507087     DOI: 10.1016/0002-9343(79)90732-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics.

Authors:  M W Johnson; W E Mitch
Journal:  Drugs       Date:  1981-03       Impact factor: 9.546

2.  Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients.

Authors:  Ben Yu-Jih Su; Han-Ming Lai; Chung-Jen Chen; Ying-Chou Chen; Chun-Kai Chiu; Ko-Ming Lin; Shan-Fu Yu; Tien-Tsai Cheng
Journal:  Clin Rheumatol       Date:  2007-11-20       Impact factor: 2.980

Review 3.  Uric acid and cardiovascular risk.

Authors:  Daniel I Feig; Duk-Hee Kang; Richard J Johnson
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

4.  Allopurinol treatment and its effect on renal function in gout: a controlled study.

Authors:  T Gibson; V Rodgers; C Potter; H A Simmonds
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

Review 5.  The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.

Authors:  Yuka Sato; Daniel I Feig; Austin G Stack; Duk-Hee Kang; Miguel A Lanaspa; A Ahsan Ejaz; L Gabriela Sánchez-Lozada; Masanari Kuwabara; Claudio Borghi; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2019-07-11       Impact factor: 28.314

Review 6.  The epidemiology and treatment of gout.

Authors:  Neil W McGill
Journal:  Open Access Rheumatol       Date:  2011-12-20

Review 7.  Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived.

Authors:  Francesca Viazzi; Giovanna Leoncini; Elena Ratto; Roberto Pontremoli
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

Review 8.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

9.  Association between xanthine dehydrogenase tag single nucleotide polymorphisms and essential hypertension.

Authors:  Baogang Wu; Ying Hao; Jin Shi; Ning Geng; Tiejun Li; Yanli Chen; Zhaoqing Sun; Liqiang Zheng; Hong Li; Naijing Li; Xingang Zhang; Yingxian Sun
Journal:  Mol Med Rep       Date:  2015-07-29       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.